Meningitis Clinical Research Trials

Birmingham : Radiant Research - Birmingham

Meningitis Vaccine Research

Birmingham : Alabama Clinical Therapeutics 806 St. Vincent's Drive, Suite 615

Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine

Huntsville : Pfizer Investigational Site

A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Chandler : Radiant Research

Meningitis Vaccine Research Study

Tucson : Radiant Research - Tucson

Meningitis Vaccine Research

Chandler : Pfizer Investigational Site

A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Bentonville : 82 Children s Inv Research Prgm (ChIRP) 2900 Medical Center Parkway, Ste. 300

Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose

Harrisburg : Pfizer Investigational Site

A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Little Rock : 83 AR Pediatric Clinical Research 500 South University, Ste. 200

Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose

Downey : Premier Health Research 9317 Firestone Blvd.

Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine

Downey : 32 Prem Health Research Center 9317 Firestone Blvd.

Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose

Oakland : Kaiser Permanente Oakland 3505 Broadway, 6th Floor, Room 624

Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine

Paramount : Center for Clinical Trials, LLC 16660 Paramount Blvd., Suite 301

Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine

Paramount : Center for Clinical Trials, LLC 16415 S. Colorado Ave., Suite 308

Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine

Pleasanton : Kaiser Permanente Pleasanton 7601 Stoneridge Drive, Second Floor

Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine

San Diego : Pfizer Investigational Site

A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

San Francisco : Pfizer Investigational Site

A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

San Francisco : Kaiser Permanente San Francisco 2200 O'Farrell St., Sixth Floor

Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine

Santa Clara : Kaiser Permanente Santa Clara 710 Lawrence Expressway, Pediatric Clinic Department

Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine

Vista : Pfizer Investigational Site

A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Denver : Radiant Research - Denver

Meningitis Vaccine Research Study

DeLand : Pfizer Investigational Site

A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Jacksonville : Pfizer Investigational Site

A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Melbourne : Pfizer Investigational Site

A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

South Miami : Pfizer Investigational Site

A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Chicago : Children's Memorial Hospital 2300 Children's Plaza, Box 155

Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine

South Bend : Pfizer Investigational Site

A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Council Bluffs : Pfizer Investigational Site

A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Wichita : Via Christi Research

Safety, Tolerance & Immunogenic Response to Vaccine for MCV4, TDaP & Bivalent rLP2086 in Children 10-12

Bardstown : Pfizer Investigational Site

A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Bardstown : Kentucky Pediatric/Adult Research 201 South Fifth Street, Suite 102

Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine

Bardstown : 27 KY Pediatric Adult Research 201 South 5th Street, Suite 102

Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose

Annapolis : 28 Annapolis Pediatrics, 200 Forbes Street, Suite 200

Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine

St. Louis : Radiant Research - St. Louis

A Clinical Research Study for Meningitis Vaccine (People 56+)

St. Louis : Radiant Research - St. Louis

Meningitis Research Study

Fremont : Pfizer Investigational Site

A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Omaha : 36 Meridian Clinical Research 3319 N. 107th Street

Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose

Hackensack : Pfizer Investigational Site

Study To Describe The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine In Laboratory Workers ≥18 To ≤65 Years Of Age

Rochester : Pfizer Investigational Site

A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Raleigh : PMG Research of Raleigh Updated

If you are a young adult, you need to know about Meningococcal Disease Type B (MnB).

Akron : Radiant Research - Akron

Meningitis Vaccine Research Study

Cleveland : Rapid Medical Research, Inc. (RMR)

Meningitis Vaccine Study: What is Meningococcal Disease Type B?

Cleveland : Pfizer Investigational Site

A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Cleveland : Senders Pediatrics 2054 South Green Road

Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine

Cleveland : 33 Dr. Sender's and Associates 2054 South Green Road

Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose

Huber Heights : Pfizer Investigational Site

A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Erie : Children's Health Care 2501 West 12th Street

Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine

Harleysville : Pennridge Pediatric Associates 270 Main Street

Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine

Hermitage : Kid's Way Pediatrics 3068 Innovation Way

Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine

Norristown : Pediatric Medical Associates 160 West Germantown Pike

Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine

Pittsburgh : UPMC

Cerebrospinal Fluid Pharmacokinetics of Daptomycin

Rydal : Pediatric Medical Associates 1077 Rydal Road

Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine

Sellersville : Pennridge Pediatric Associates 711 Lawn Avenue

Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine

Upper St. Clair : PEAK Research 2859 Washington Rd., Ste. 412B

Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine

Anderson : Radiant Research - Anderson

Meningitis Vaccine (Pediatric) Research Study

Anderson : Radiant Research - Anderson

What's News @ Radiant Research Anderson

Mt. Pleasant : Coastal Carolina Research Center

Healthy volunteers (ages 10 to 25) needed for vaccine research study for prevention of meningitis

Mt. Pleasant : Coastal Carolina Research Center

Healthy volunteers (Ages 11 to 25) needed for vaccine research study for prevention of meningitis.

Mt. Pleasant : Pfizer Investigational Site

A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Nashville : Clinical Research Associates, Inc.

Meningitis B Vaccine Study

Bristol : Pfizer Investigational Site

A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Dallas : Research Across America Updated

Meningococcal Vaccine Research Study

Dallas : Radiant Research - Dallas, North

Vaccine Research for Meningitis B

Houston : DM Clinical Research

Pediatric Meningitis Vaccine- Houston,TX

Austin : Pfizer Investigational Site

A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Dallas : Pfizer Investigational Site

A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Fort Worth : Pfizer Investigational Site

A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Fort Worth : 31 Benchmark Research, Fort Worth 4504 Boat Club Rd., Suite 400A

Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose

Houston : Pfizer Investigational Site

A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Katy : Pfizer Investigational Site

A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

San Angelo : 25 Benchmark Research, San Angelo 3555 Knickerbocker Rd.

Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose

San Antonio : Pfizer Investigational Site

A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Murray : Radiant Research - Salt Lake City

Meningitis Research Study

Murray : Radiant Research - Salt Lake City

Vaccine Research for Meningitis B

Salt Lake City : J. Lewis Research, Inc.

Meningitis B Vaccine

West Jordan : Advanced Clinical Research, UT

Meningitis Type B Vaccine

Clinton : 65 Westside Medical 1477 N 2000 W, Suite C

Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose

Salt Lake City : Pfizer Investigational Site

A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Salt Lake City : 29 J. Lewis Research, Inc. 6360 South 3000 East, Ste. 100

Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose

Salt Lake City : 30 J. Lewis Research, Inc. 6360 South 3000 East, Ste. 100

Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose

South Jordan : Pfizer Investigational Site

A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

South Jordan : 37 Copperview Medical Associates 3556 West 9800 South

Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose

Syracuse : 47 Wee Care Pediatrics 1792 W. 1700 S.

Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose

West Jordan : Pfizer Investigational Site

A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Burke : Pfizer Investigational Site

A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Charlottesville : Pfizer Investigational Site

A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Spokane : 34 Rockwood Clinic P S 400 East Fifth Avenue

Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose

Spokane : 35 Rockwood Clinic-North Pediatrics 9001 N Country Homes Blvd

Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose

Maroubra : Pfizer Investigational Site

A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

North Adelaide : Pfizer Investigational Site

A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Sherwood : Pfizer Investigational Site

A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Subiaco : Pfizer Investigational Site

A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Westmead : Pfizer Investigational Site

A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Leuven :

A Study of Doripenem in CerebrospinalFluid After Doripenem Administration in Pediatric Patients Less Than 1 Year of Age

Rua Borges Lagoa 770 : Site 53 - CRIE UNIFESP

A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years

Rua Marselhesa 500 Vila Clementino : Site 50 - Associacao Fundo de Incentivo a Psicofarmacologia

A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years

Bujumbura : CHU Kamenge

Study Evaluating Efficiency and Tolerance of High-dose Fluconazole Associated With Flucytosine as Induction Therapy for Cryptococcal Meningitis Associated With HIV in Burundi

Bujumbura : Hôpital Prince Régent Charles

Study Evaluating Efficiency and Tolerance of High-dose Fluconazole Associated With Flucytosine as Induction Therapy for Cryptococcal Meningitis Associated With HIV in Burundi

Bururi : Hôpital général

Study Evaluating Efficiency and Tolerance of High-dose Fluconazole Associated With Flucytosine as Induction Therapy for Cryptococcal Meningitis Associated With HIV in Burundi

Kayanza : Hôpital général

Study Evaluating Efficiency and Tolerance of High-dose Fluconazole Associated With Flucytosine as Induction Therapy for Cryptococcal Meningitis Associated With HIV in Burundi

Muyinga : Hôpital général

Study Evaluating Efficiency and Tolerance of High-dose Fluconazole Associated With Flucytosine as Induction Therapy for Cryptococcal Meningitis Associated With HIV in Burundi

Ceska Skalice : Ordinace praktickeho lekare pro deti a dorost

Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1

Chlumec nad Cidlinou : Ordinace praktickeho lekare pro deti a dorost

Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1

Holice : Ordinace praktickeho lekare pro deti a dorost

Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1

Hradec Kralove : Biovomed

Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1

Hradec Kralove : Fakulta vojenskeho zdravotnictvi UO

Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1

Hradec Králové : Ordinace praktickeho lekare pro deti a dorost

Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1

Hradec Králové : Ordinace praktickeho lekare pro deti a dorost

Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1

Hronov : Ordinace praktickeho lekare pro deti a dorost

Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1

Hronov : Ordinace praktickeho lekare pro deti a dorost

Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1

Jaromer : Ordinace praktickeho lekare pro deti a dorost

Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1

Jaromer : Ordinace praktickeho lekare pro deti a dorost

Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1

Jindrichuv Hradec : Pfizer Investigational Site

A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Jindrichuv Hradec : Ordinace praktickeho lekare pro deti a dorost

Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1

Jindrichuv Hradec : Ordinace praktickeho lekare pro deti a dorost

Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1

Jindrichuv Hradec : Ordinace praktickeho lekare pro deti a dorost

Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1

Nachod : Nemocnice Náchod

Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1

Pardubice : Ordinace praktickeho lekare pro deti a dorost

Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1

Pardubice : Ordinace praktickeho lekare pro deti a dorost

Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1

Pardubice : Nemocnice Pardubice

Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1

Plzen : Pfizer Investigational Site

A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Praha 2 : Pfizer Investigational Site

A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Sezemice : Ordinace praktickeho lekare pro deti a dorost

Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1

Tynec nad Sazavou : Pfizer Investigational Site

A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Aarhus N : Pfizer Investigational Site

A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Rakvere : Pfizer Investigational Site

A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Tallinn : Pfizer Investigational Site

A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Pori : Pfizer Investigational Site

A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Tampere : Pfizer Investigational Site

A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Turku : Pfizer Investigational Site

A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Caen : François Baclesse Center

Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous Meningitis

Lille : Oscar Lambret Center

Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous Meningitis

Lyon : Léon Bérard Center

Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous Meningitis

Paris : Institut Curie - Claudius Regaud Hospital

Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous Meningitis

Paris : Pitie Salpetriere Hospital

Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous Meningitis

Saint-Cloud : Rene Huguenin Hospital

Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous Meningitis

Marburg : Praxis Dr. W. Schuermann

Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-risk Adults

Florence : Universita di Firenze -Pediatria

Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1

Milan : IRCCS Cà Granda

Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1

Novara : Ospedale Maggiore della Carita

Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1

Padova : Dip Pediatria AO Padova

Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1

Siena : UOC Medicina Interna 2, azienda Ospedaliera Universitaria Senese

Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-risk Adults

Kaunas : Pfizer Investigational Site

A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Vilnius : Pfizer Investigational Site

A Global Phase 3 Safety Study of 120 Mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Alaminos City :